Alumis Q2 net income $59.3M (incl. $187.9M merger gain); Phase 3 psoriasis & Phase 2b SLE enrollment complete

ALUMIS INC.

2025-Q2 EPS reported -$0.61 revenue$20,055,000

Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.
Phase 3 ONWARD trials (psoriasis) fully enrolled; topline data expected early Q1 2026.
Phase 2b LUMUS trial (SLE) fully enrolled with 408 patients; topline data expected Q3 2026.
Completed merger with ACELYRIN, adding $382.6M cash; total merger-related expenses of $26.8M in Q2.
R&D expenses $108.8M (up from $48.6M); G&A $34.5M (up from $7.6M) driven by merger costs and clinical acceleration.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.